Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511767 | 0.80 | MAOB (0.40) | CYP2C19 | |
| SCHEMBL4027132 | 0.73 | HMOX1 (0.48) | MEN1KMT2ATRPV1CYP3A4CYP2C9 | |
| SCHEMBL4857157 | 0.72 | TBXAS1 (0.41) | ALDH1A1LMNA | |
| SCHEMBL12185258 | 0.71 | HTT (0.37) | ALDH1A1THRB | |
| SCHEMBL19973954 | 0.70 | DPP4 (0.43) | MEN1ALDH1A1MAPTKMT2ACYP3A4 | |
| SCHEMBL217356 | 0.70 | ALDH1A1 (0.42) | MEN1ALDH1A1MAPTKMT2ACYP2C9 | |
| SCHEMBL2152993 | 0.70 | TBXAS1 (0.38) | ALDH1A1LMNA | |
| SCHEMBL12016599 | 0.70 | LMNA (0.42) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL20511850 | 0.70 | TBXAS1 (0.34) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL25679817 | 0.69 | MBOAT4 (0.41) | MBOAT4TRPV1CYP3A4CYP2C9CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131502-A1 | Biologically active compounds | QUIBELL MARTIN | 2009-05-21 | — | — | US | disclosed |
| WO-2007023281-A2 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131502-A1 | Biologically active compounds | COLGALT1, SOST, COL1A1 | MBOAT4 2166/4885MEN1 185/4885ALDH1A1 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.